CHLORHEXIDINE GLUCONATE 0.12% ORAL RINSE, USP MOUTHWASH

Country: Canada

Language: English

Source: Health Canada

Active ingredient:

CHLORHEXIDINE GLUCONATE

Available from:

SAGE PRODUCTS LLC

ATC code:

A01AB03

INN (International Name):

CHLORHEXIDINE

Dosage:

0.12%

Pharmaceutical form:

MOUTHWASH

Composition:

CHLORHEXIDINE GLUCONATE 0.12%

Administration route:

BUCCAL

Units in package:

15ML/473ML

Prescription type:

Prescription

Therapeutic area:

MISCELLANEOUS ANTI-INFECTIVES

Product summary:

Active ingredient group (AIG) number: 0107629007; AHFS:

Authorization status:

CANCELLED POST MARKET

Authorization date:

2022-04-22

Summary of Product characteristics

_ _
_ _
_Page 1 of 19_
PRODUCT MONOGRAPH
CHLORHEXIDINE GLUCONATE 0.12% ORAL RINSE, USP
Chlorhexidine Gluconate 0.12% Oral Rinse
Liquid, 0.12% Chlorhexidine Gluconate
Antigingivital Oral Rinse
Sage Product LLC
3909 Three Oaks Road
Cary, IL 60013
USA
Date of Preparation:
February 17, 2015
Submission Control No: 180308
_ _
_ _
_Page 2 of 19_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................6
DOSAGE AND ADMINISTRATION
................................................................................6
OVERDOSAGE
..................................................................................................................7
ACTION AND CLINICAL PHARMACOLOGY
..............................................................8
STORAGE AND STABILITY
............................................................................................9
SPECIAL HANDLING INSTRUCTIONS
.........................................................................9
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................10
PART II: SCIENTIFIC INFORMATION
...............................................................................11
PHARMACEUTICAL INFORMATION
..........................................................................11
CLINICAL TRIALS
..........................................................................................................12
DETAILED PHARMACOLOGY
.........................